Physician profile
Lin Xu
NPI 1184675712
$8,813.31
in general payments reported to CMS, 2019-2025
25 companies · $380 in 2025
The $380 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,090 · 2020: $500 · 2021: $1,101 · 2022: $1,442 · 2023: $1,928 · 2024: $1,371 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,680.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,370.45 | 2019-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $1,059.14 | 2019-2024 | Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $1,035.46 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $929.61 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Vanda Pharmaceuticals INC. | $797.43 | 2019-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $644.29 | 2021-2025 | Caplyta |
| Lundbeck LLC | $542.71 | 2019-2024 | Rexulti |
| Neurocrine Biosciences, INC. | $420.78 | 2019-2024 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $418.66 | 2019-2022 | |
| Abbvie INC. | $388.29 | 2021-2025 | Vraylar |
| Allergan, INC. | $331.28 | 2019 | |
| Indivior INC. | $297.68 | 2022-2024 | Perseris |
| Takeda Pharmaceuticals U.S.A., INC. | $226.42 | 2020-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $87.07 | 2019-2023 | Belsomra |
| Eisai INC. | $55.63 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $40.12 | 2019 | |
| Idorsia Pharmaceuticals US INC | $27.85 | 2023-2024 | Quviviq |
| Noven Therapeutics, LLC | $24.81 | 2025 | Secuado, Xelstrym |
| Biogen, INC. | $23.94 | 2024 | |
| Supernus Pharmaceuticals, INC. | $21.84 | 2023 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $20.09 | 2024 | Cobenfy |
| Collegium Pharmaceutical, INC. | $15.75 | 2025 | Jornay Pm |
| Bausch Health US, LLC | $12.03 | 2020 | |
| Tris Pharma INC | $11.05 | 2020 | |
| Avanir Pharmaceuticals, INC. | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lin Xu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.